Starpharma Holdings Limited
SPHRY
Other OTC5.19
USD
+0.19
- -
Starpharma Holdings Limited
SPHRY
(Other OTC)
Recent
price
5.19
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Starpharma Holdings Limited is an Australian biotechnology company specializing in the research, development, and commercialization of dendrimer-based products primarily for pharmaceutical, life sciences, and medical applications. The company’s core products include VivaGel®, a non-antibiotic vaginal gel for the treatment and prevention of bacterial vaginosis; VivaGel® Condom, a condom coating with antiviral properties; and VIRALEZE™, an antiviral nasal spray designed to reduce respiratory viral infections. Starpharma also focuses on advancing its proprietary DEP® (dendrimer enhanced product) drug delivery platform, which enhances the efficacy and safety of therapeutic compounds, with a significant emphasis on oncology and infectious diseases. The company’s pipeline comprises dendrimer-drug conjugates and nanoparticle formulations targeting challenging cancers and viral infections. Starpharma operates globally, with commercial products launched in multiple countries and clinical development programs ongoing in key regions including Australia, the United States, and Europe. Founded in 1998 and headquartered in Melbourne, Australia, the company leverages its extensive intellectual property portfolio in dendrimer technology. Recent major developments include a strategic collaboration and licensing agreement with Genentech, a US-based biotechnology company, to develop cancer therapies using Starpharma’s DEP drug delivery platform. The company also entered a partnership with Radiopharm Theranostics to develop radiopharmaceutical dendrimer drug conjugates for targeted cancer treatment. In addition, Starpharma established a UK-based oncology company, Petalion Therapeutics, in partnership with Medicxi, focused on targeted dendrimer cancer therapies. In 2024, Starpharma completed the sale of its agrochemical business, including its Priostar® dendrimer technology, to Agrium for AUD 35 million to sharpen its focus on pharmaceutical applications. These initiatives reflect Starpharma’s strategic shift toward expanding its drug delivery platform and oncology pipeline while capitalizing on collaborations with major pharmaceutical players. Starpharma’s business model centers on innovating dendrimer nanotechnology for improved drug performance and commercializing products addressing unmet medical needs in infectious diseases and oncology. The company’s product and service offerings span anti-infective consumer products, advanced clinical-stage drug delivery systems, and novel therapeutic candidates in oncology, supported by ongoing global partnerships and clinical programs.
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma
Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
Starpharma Up With News, Down With None; Timing Entry Makes Sense
Starpharma signs DEP® ADC Research Agreement with MSD
Starpharma Viraleze: COVID-19 Nasal Spray Development